Acute Porphyria Drug Database

A02BX05 - Bismuth Subcitrate
Propably not porphyrinogenic
PNP

Rationale
Bismuth citrate is an inorganic salt and it is not metabolized. No porphyrinogenic effects are expected.
Chemical description
Bismuth subcitrate (bismuth tripotassium dicitrate) is a salt of bismuth, potassium and citric acid (Drug Bank).
Therapeutic characteristics
Bismuth citrate is used in the treatment of gastroduodenal disorders and may be used in combination with other drugs for eradication of Helicobacter pylori. It is administrated orally.
Metabolism and pharmacokinetics
Bismuth is widely distributed throughout the entire body, and is eliminated through urinary and biliary routes. Half-life of 5 days suggests tissue accumulation (FDA). No studies of CYP interaction potential is identified, but this is not expected.

References

  1. Drug reference publications
  2. DrugBank. Bismuth subcitrate. #1054
  3. Government bodies
  4. U.S. Food and Drug Administration (FDA). Label information PYLERA. (Revised: 01.2018). #1055

Similar drugs
Explore alternative drugs in similar therapeutic classes A02B / A02BX or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙